European MPs call for urgent action against antimicrobial resistance

Ahead of World Antimicrobial Awareness Week, the EU Parliament hosted an event where members of the European Parliament (MEPs) joined with Japanese pharmaceutical company, Shionogi, the Active Citizenship Network and the

Infex doses first patients in Pseudomonas aeruginosa phase 1 study

There are currently no approved preventative treatments for Pa infection. RESP-X, in-licensed from Shionogi, is a novel humanised monoclonal antibody designed to help the body tackle Pa infections by

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement follows positive results from a phase 3 trial of ensitrelvir in patients with mild to moderate symptoms of COVID-19, announced by Shionogi last month. ... Takuko Sawada, director and vice chairperson of the Shionogi Board, said: “Shionogi

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms. Shionogi’s ensitrelvir fumaric acid (ensitrelvir) – an investigational protease inhibitor being evaluated as an antiviral treatment for COVID-19 – demonstrated a ... We will continue

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]